Abstract
Introduction of diffusion tensor imaging (DTI) in 1980 and its advancement in the last three decades offered the possibility to visualize and quantify changes in white matter. DTI allows the evaluation of the structural integrity in complex neurodegenerative diseases, such as Alzheimer’s disease (AD). Progressive disintegration of functional and structural neural network coordination contributes to the cognitive dysfunction in AD. Therefore, detection of loss of cortico-cortical projections may support an early diagnosis at prodromal stages of disease which may prove essential for future preventive AD treatment trials. Moreover, structural integrity measured by DTI may help to distinguish between symptomatic and disease modifying effects of pharmacological interventions. This review gives a concise account on the physical basis of DTI acquisition and processing. We summarize DTI findings in normal aging and AD and regarding the effects of cognitive intervention and antidementive treatment on structural neural connectivity. Finally, we evaluate the promising future potential of DTI to become a surrogate endpoint in clinical AD trials.
Keywords: Neuronal integrity, early diagnosis, tissue structure, mild cognitive impairment.
Current Pharmaceutical Design
Title:Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease
Volume: 19 Issue: 36
Author(s): Ingo Kilimann, Yuttachai Likitjaroen, Harald Hampel and Stefan Teipel
Affiliation:
Keywords: Neuronal integrity, early diagnosis, tissue structure, mild cognitive impairment.
Abstract: Introduction of diffusion tensor imaging (DTI) in 1980 and its advancement in the last three decades offered the possibility to visualize and quantify changes in white matter. DTI allows the evaluation of the structural integrity in complex neurodegenerative diseases, such as Alzheimer’s disease (AD). Progressive disintegration of functional and structural neural network coordination contributes to the cognitive dysfunction in AD. Therefore, detection of loss of cortico-cortical projections may support an early diagnosis at prodromal stages of disease which may prove essential for future preventive AD treatment trials. Moreover, structural integrity measured by DTI may help to distinguish between symptomatic and disease modifying effects of pharmacological interventions. This review gives a concise account on the physical basis of DTI acquisition and processing. We summarize DTI findings in normal aging and AD and regarding the effects of cognitive intervention and antidementive treatment on structural neural connectivity. Finally, we evaluate the promising future potential of DTI to become a surrogate endpoint in clinical AD trials.
Export Options
About this article
Cite this article as:
Kilimann Ingo, Likitjaroen Yuttachai, Hampel Harald and Teipel Stefan, Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease, Current Pharmaceutical Design 2013; 19 (36) . https://dx.doi.org/10.2174/1381612811319360003
DOI https://dx.doi.org/10.2174/1381612811319360003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Current Medicinal Chemistry Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?
CNS & Neurological Disorders - Drug Targets Relationship of Neurofilament Light (NfL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia
Current Alzheimer Research Current Strategies and Novel Drug Approaches for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography
Current Drug Targets Genomic Linkage Between Alzheimer's Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Drug-Related Decrease in Neuropsychological Functions of Abstinent Drug Users
Current Drug Abuse Reviews Therapeutics Targeting Nogo-A Hold Promise for Stroke Restoration
CNS & Neurological Disorders - Drug Targets P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets [<sup>18</sup>F]Amylovis as a Potential PET Probe for β-Amyloid Plaque: Synthesis, <i>In Silico, In vitro</i> and <i>In vivo</i> Evaluations
Current Radiopharmaceuticals Correlation Analysis of Capillary APOE, VEGF and eNOS Expression in Alzheimer Brains
Current Alzheimer Research Editorial: Current Approaches in the Treatment of Neuropsychiatric Diseases
Current Topics in Medicinal Chemistry Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Expression and Function of Organic Cation and Anion Transporters (SLC22 Family) in the CNS
Current Pharmaceutical Design Statins, Risk of Death and Ischemic Stroke in Patients with Dementia: A Registry-Based Observational Cohort Study
Current Alzheimer Research Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Connections Between Herpes Simplex Virus Type 1 and Alzheimer's Disease Pathogenesis
Current Alzheimer Research Overlapping Molecular Signatures in Parkinson's Patient Leukocytes Before and After Treatment and in Mouse Model Brain Regions
CNS & Neurological Disorders - Drug Targets Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research